Koen van Besien

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6302542/publications.pdf

Version: 2024-02-01

392 papers	15,783 citations	19657 61 h-index	22166 113 g-index
399 all docs	399 docs citations	399 times ranked	10135 citing authors

#	Article	IF	Citations
1	Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy. Blood, 1997, 89, 4531-4536.	1.4	1,101
2	Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts [see comments]. Blood, 1995, 85, 1659-1665.	1.4	549
3	Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation.. Journal of Clinical Oncology, 1989, 7, 932-939.	1.6	346
4	Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood, 2003, 102, 3521-3529.	1.4	339
5	CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood, 1995, 86, 4337-4343.	1.4	323
6	A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood, 2008, 112, 2667-2674.	1.4	320
7	Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood, 1997, 89, 4531-6.	1.4	294
8	Multicenter Analysis of 80 Solid Organ Transplantation Recipients With Post-Transplantation Lymphoproliferative Disease: Outcomes and Prognostic Factors in the Modern Era. Journal of Clinical Oncology, 2010, 28, 1038-1046.	1.6	290
9	Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy- 1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood, 1995, 86, 2842-2848.	1.4	272
10	Risk Factors, Treatment, and Outcome of Central Nervous System Recurrence in Adults With Intermediate-Grade and Immunoblastic Lymphoma. Blood, 1998, 91, 1178-1184.	1.4	265
11	Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer.. Journal of Clinical Oncology, 1998, 16, 986-993.	1.6	237
12	Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Annals of Oncology, 2007, 18, 1071-1079.	1.2	232
13	Risk Factors for Acute Graft-Versus-Host Disease After Allogeneic Blood Stem Cell Transplantation. Blood, 1999, 94, 1465-1470.	1.4	217
14	Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica, 2014, 99, 1373-1379.	3.5	213
15	Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplantation, 1997, 19, 977-982.	2.4	209
16	Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma. Journal of Clinical Oncology, 2013, 31, 3100-3109.	1.6	206
17	Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood, 2001, 98, 1695-1700.	1.4	202
18	Autologous Transplantation for Diffuse Aggressive Non-Hodgkinâ€™s Lymphoma in Patients Never Achieving Remission: A Report from the Autologous Blood and Marrow Transplant Registry. Journal of Clinical Oncology, 2001, 19, 406-413.	1.6	194

#	Article	IF	Citations
19	Allogeneic bone marrow transplantation for low-grade lymphoma. Blood, 1998, 92, 1832-6.	1.4	190
20	Autotransplants for Hodgkin's Disease in Patients Never Achieving Remission: A Report From the Autologous Blood and Marrow Transplant Registry. Journal of Clinical Oncology, 1999, 17, 534-534.	1.6	186
21	Temsirolimus Has Activity in Nonâ€“Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium. Journal of Clinical Oncology, 2010, 28, 4740-4746.	1.6	181
22	Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood, 2011, 118, 6438-6445.	1.4	158
23	Allogeneic Transplants in Follicular Lymphoma: Higher Risk of Disease Progression after Reduced-Intensity Compared to Myeloablative Conditioning. Biology of Blood and Marrow Transplantation, 2008, 14, 236-245.	2.0	157
24	A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood, 2003, 101, 2476-2482.	1.4	155
25	Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood, 2013, 122, 3863-3870.	1.4	153
26	Parvovirus B19-induced perturbation of human megakaryocytopoiesis in vitro. Blood, 1990, 76, 1997-2004.	1.4	151
27	Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood, 2002, 99, 2255-2258.	1.4	148
28	Cytokine-dependent long-term culture of highly enriched precursors of hematopoietic progenitor cells from human bone marrow.. Journal of Clinical Investigation, 1990, 86, 932-941.	8.2	147
29	Syngeneic Hematopoietic Stem-Cell Transplantation for Non-Hodgkinâ€™s Lymphoma: A Comparison With Allogeneic and Autologous Transplantationâ€”The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 2003, 21, 3744-3753.	1.6	146
30	Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood, 2009, 113, 5074-5082.	1.4	143
31	Fludarabine, Melphalan, and Alemtuzumab Conditioning in Adults With Standard-Risk Advanced Acute Myeloid Leukemia and Myelodysplastic Syndrome. Journal of Clinical Oncology, 2005, 23, 5728-5738.	1.6	134
32	Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematology,the, 2017, 4, e431-e442.	4.6	132
33	Primary Mediastinal B-Cell Lymphoma: A Review of Pathology and Management. Journal of Clinical Oncology, 2001, 19, 1855-1864.	1.6	129
34	Progressive Improvement in Cutaneous and Extracutaneous Chronic Graft-versus-Host Disease after a 24-Week Course of Extracorporeal Photopheresisâ€”Results of a Crossover Randomized Study. Biology of Blood and Marrow Transplantation, 2011, 17, 1775-1782.	2.0	127
35	NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 1467-1503.	2.0	125
36	Performance Status and Comorbidity Predict Transplant-Related Mortality After Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2006, 12, 954-964.	2.0	122

#	Article	IF	Citations
37	Fatigue and Physical Activity in Patients Undergoing Hematopoietic Stem Cell Transplant. Oncology Nursing Forum, 2006, 33, 614-624.	1.2	122
38	Pilot Study of Comprehensive Geriatric Assessment (CGA) in Allogeneic Transplant: CGA Captures a High Prevalence of Vulnerabilities in Older Transplant Recipients. Biology of Blood and Marrow Transplantation, 2013, 19, 429-434.	2.0	111
39	Prior invasive fungal infection does not preclude successful allogeneic transplantation. Biology of Blood and Marrow Transplantation, 2006, 12, 34.	2.0	110
40	Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplantation, 2015, 50, 1227-1234.	2.4	109
41	Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood, 2004, 104, 3797-3803.	1.4	108
42	Allogeneic bone marrow transplantation for poor-prognosis lymphoma: Response, toxicity, and survival depend on disease histology. American Journal of Medicine, 1996, 100, 299-307.	1.5	106
43	Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplantation, 2001, 27, 387-396.	2.4	106
44	Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graftâ€versusâ€host disease. British Journal of Haematology, 1997, 97, 466-473.	2.5	102
45	Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood, 1993, 82, 2324-2328.	1.4	100
46	Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2009, 15, 109-117.	2.0	98
47	Simultaneous Generation of CD8+ and CD4+ Melanoma-Reactive T Cells by Retroviral-Mediated Transfer of a Single T-Cell Receptor. Cancer Research, 2005, 65, 1570-1576.	0.9	97
48	Cutting Edge: Activation of the p38 Mitogen-Activated Protein Kinase Signaling Pathway Mediates Cytokine-Induced Hemopoietic Suppression in Aplastic Anemia. Journal of Immunology, 2002, 168, 5984-5988.	0.8	93
49	Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplantation, 2018, 53, 449-456.	2.4	92
50	Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease. Bone Marrow Transplantation, 2000, 26, 445-449.	2.4	91
51	A Comparison of HLA-Identical Sibling Allogeneic versus Autologous Transplantation for Diffuse Large BâCell Lymphoma: A Report from the CIBMTR. Biology of Blood and Marrow Transplantation, 2010, 16, 35-45.	2.0	88
52	Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. Blood Advances, 2020, 4, 560-572.	5.2	88
53	Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2006, 12, 541-551.	2.0	84
54	BK Virus Infection Is Associated with Hematuria and Renal Impairment in Recipients of Allogeneic Hematopoetic Stem Cell Transplants. Biology of Blood and Marrow Transplantation, 2009, 15, 1038-1048.e1.	2.0	80

#	Article	IF	Citations
55	Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood, 1993, 82, 2324-2328.	1.4	78
56	Allogeneic blood stem cell transplantation in advanced hematologic cancers. Bone Marrow Transplantation, 1997, 19, 455-460.	2.4	76
57	Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. Biology of Blood and Marrow Transplantation, 2016, 22, 1348-1356.	2.0	76
58	Pretreatment C-Reactive Protein Is a Predictor for Outcomes after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 1209-1216.	2.0	75
59	Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2007, 40, 1027-1032.	2.4	74
60	Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood, 1998, 91, 1178-84.	1.4	70
61	Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplantation, 1999, 24, 763-768.	2.4	66
62	Associations between acute gastrointestinal GvHD and the baseline gut microbiota of allogeneic hematopoietic stem cell transplant recipients and donors. Bone Marrow Transplantation, 2017, 52, 1643-1650.	2.4	63
63	Allogeneic stem cell transplantation for sickle cell disease. A study of patients' decisions. Bone Marrow Transplantation, 2001, 28, 545-549.	2.4	62
64	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Follicular Lymphoma: An Evidence-Based Review. Biology of Blood and Marrow Transplantation, 2010, 16, 443-468.	2.0	60
65	Bone marrow transplantation after failure of autologous transplant for non-Hodgkinâ€™s lymphoma. Bone Marrow Transplantation, 1997, 19, 121-127.	2.4	59
66	CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood, 1995, 86, 4337-43.	1.4	59
67	High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome.. Journal of Clinical Oncology, 1998, 16, 63-69.	1.6	58
68	Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD without Affecting Long-Term Outcomes. Biology of Blood and Marrow Transplantation, 2009, 15, 610-617.	2.0	58
69	Second Autologous Stem Cell Transplantation for Relapsed Lymphoma after a Prior Autologous Transplant. Biology of Blood and Marrow Transplantation, 2008, 14, 904-912.	2.0	56
70	Paucity of HLA-Identical Unrelated Donors for African-Americans with Hematologic Malignancies: The Need for New Donor Options. Biology of Blood and Marrow Transplantation, 2008, 14, 938-941.	2.0	55
71	Older Age But Not Donor Health Impairs Allogeneic Granulocyte Colony-Stimulating Factor (G-CSF) Peripheral Blood Stem Cell Mobilization. Biology of Blood and Marrow Transplantation, 2009, 15, 1394-1399.	2.0	55
72	Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplantation, 2005, 35, 965-970.	2.4	53

#	Article	IF	Citations
73	Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy. Scientific Reports, 2019, 9, 10634.	3.3	53
74	Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue.. Journal of Clinical Oncology, 1997, 15, 667-673.	1.6	52
75	Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma. Biology of Blood and Marrow Transplantation, 2009, 15, 1455-1464.	2.0	52
76	DAS181 for Treatment of Parainfluenza Virus Infections inÂHematopoietic Stem Cell Transplant Recipients at a Single Center. Biology of Blood and Marrow Transplantation, 2016, 22, 965-970.	2.0	52
77	Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leukemia and Lymphoma, 2009, 50, 1809-1817.	1.3	50
78	Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer, 2003, 97, 1242-1247.	4.1	49
79	Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Annals of Oncology, 1999, 10, 527-529.	1.2	48
80	Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance. Bone Marrow Transplantation, 2008, 41, 505-513.	2.4	48
81	Advances in mobilization for the optimization of autologous stem cell transplantation. Leukemia and Lymphoma, 2009, 50, 1412-1421.	1.3	48
82	Acquired Cyclic Amegakaryocytic Thrombocytopenia Associated with an Immunoglobulin Blocking the Action of Granulocyteâ€“Macrophage Colony-Stimulating Factor. New England Journal of Medicine, 1989, 321, 97-102.	27.0	47
83	Low-Grade Lymphoma. Hematology American Society of Hematology Education Program, 2004, 2004, 203-220.	2.5	47
84	Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplantation, 2004, 33, 1015-1023.	2.4	47
85	Arterial thrombosis in four patients treated with thalidomide. Leukemia and Lymphoma, 2005, 46, 239-242.	1.3	47
86	Safety and efficacy of plerixafor dose escalation for the mobilization of CD34 ⁺ hematopoietic progenitor cells in patients with sickle cell disease: interim results. Haematologica, 2018, 103, 770-777.	3.5	47
87	Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies.. Journal of Clinical Oncology, 1994, 12, 1923-1930.	1.6	45
88	Regimen-related toxicity after fludarabineâ€“melphalan conditioning: a prospective study of 31 patients with hematologic malignancies. Bone Marrow Transplantation, 2003, 32, 471-476.	2.4	45
89	High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. Bone Marrow Transplantation, 1995, 15, 549-55.	2.4	45
90	Influence of Age and Histology on Outcome in Adult Non-Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT): A Report from The Center For International Blood & Marrow Transplant Research (CIBMTR). Biology of Blood and Marrow Transplantation, 2008, 14, 1323-1333.	2.0	44

#	Article	IF	Citations
91	MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab. Clinical and Experimental Immunology, 2020, 203, 96-104.	2.6	44
92	Simultaneous use of Rhodamine 123, phycoerythrin, Texas red, and allophycocyanin for the isolation of human hematopoietic progenitor cells. Cytometry, 1991, 12, 179-183.	1.8	43
93	Intravesicular carboprost for the treatment of hemorrhagic cystitis after marrow transplantation. Urology, 1995, 46, 811-815.	1.0	42
94	Impact of preexisting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies.. Journal of Clinical Oncology, 1996, 14, 3036-3042.	1.6	42
95	Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplantation, 2006, 37, 307-310.	2.4	42
96	Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy. Biology of Blood and Marrow Transplantation, 2016, 22, 2100-2103.	2.0	42
97	KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation. Blood Advances, 2020, 4, 740-754.	5.2	42
98	Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience. Bone Marrow Transplantation, 2005, 35, 253-260.	2.4	41
99	Relapsing polychondritis: A paraneoplastic syndrome associated with myelodysplastic syndromes. American Journal of Hematology, 1992, 40, 47-50.	4.1	40
100	Regulation of myeloma cell growth through Akt/Gsk3/forkhead signaling pathway. Biochemical and Biophysical Research Communications, 2002, 297, 760-764.	2.1	40
101	Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leukemia and Lymphoma, 2010, 51, 2240-2249.	1.3	40
102	Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 913-921.	2.0	40
103	National Cancer Instituteâ€™s First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Summary and Recommendations from the Organizing Committee. Biology of Blood and Marrow Transplantation, 2011, 17, 443-454.	2.0	39
104	Allogeneic transplantation for AML and MDS: GVL versus GVHD and disease recurrence. Hematology American Society of Hematology Education Program, 2013, 2013, 56-62.	2.5	39
105	ALLOGENEIC TRANSPLANTATION FOR ADVANCED LEUKEMIA. Transplantation, 1996, 62, 1806-1810.	1.0	39
106	Osteopontin Regulates Actin Cytoskeleton and Contributes to Cell Proliferation in Primary Erythroblasts. Journal of Biological Chemistry, 2008, 283, 6997-7006.	3.4	38
107	Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2010, 45, 1068-1076.	2.4	38
108	Maternal microchimerism is prevalent in cord blood in memory T cells and other cell subsets, and persists post-transplant. OncoImmunology, 2017, 6, e1311436.	4.6	38

#	Article	IF	Citations
109	Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide. Lancet Oncology, The, 2006, 7, 436-438.	10.7	37
110	Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment. Leukemia and Lymphoma, 2008, 49, 52-58.	1.3	37
111	Allotransplantation for Patients Age â‰¥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. Biology of Blood and Marrow Transplantation, 2014, 20, 960-968.	2.0	37
112	Allogeneic and autologous transplantation for chronic lymphocytic leukemia. Leukemia, 2001, 15, 1317-1325.	7.2	36
113	Naturally acquired microchimerism. Chimerism, 2014, 5, 24-39.	0.7	36
114	Clinical and molecular epidemiology of human rhinovirus infections in patients with hematologic malignancy. Journal of Clinical Virology, 2015, 71, 51-58.	3.1	36
115	Umbilical Cord Blood Transplantation Supported by Third-Party Donor Cells: Rationale, Results, andÂApplications. Biology of Blood and Marrow Transplantation, 2013, 19, 682-691.	2.0	35
116	Complete Remission of Refractory Gestational Trophoblastic Disease with Brain Metastases Treated with Multicycle Ifosfamide, Carboplatin, and Etoposide (ICE) and Stem Cell Rescue. Gynecologic Oncology, 1997, 65, 366-369.	1.4	34
117	Pilot Trial of Interleukin-2 With Granulocyte Colony-Stimulating Factor for the Mobilization of Progenitor Cells in Advanced Breast Cancer Patients Undergoing High-Dose Chemotherapy: Expansion of Immune Effectors Within the Stem-Cell Graft and Postâ€“Stem-Cell Infusion. Journal of Clinical Oncology, 2001, 19, 634-644.	1.6	34
118	Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. Bone Marrow Transplantation, 2001, 28, 557-562.	2.4	34
119	Colonization With Levofloxacin-resistant Extended-spectrum Î²-Lactamase-producing Enterobacteriaceae and Risk of Bacteremia in Hematopoietic Stem Cell Transplant Recipients. Clinical Infectious Diseases, 2018, 67, 1720-1728.	5.8	34
120	Unrelated Donor Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: Long-Term Outcomes. Biology of Blood and Marrow Transplantation, 2009, 15, 554-563.	2.0	33
121	Alemtuzumab in allogeneic hematopoetic stem cell transplantation. Expert Opinion on Biological Therapy, 2011, 11, 1099-1111.	3.1	31
122	Identification by random forest method of HLA class I amino acid substitutions associated with lower survival at day 100 in unrelated donor hematopoietic cell transplantation. Bone Marrow Transplantation, 2012, 47, 217-226.	2.4	31
123	Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104. Blood, 2010, 116, 37-37.	1.4	31
124	The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients. Leukemia and Lymphoma, 2014, 55, 2858-2865.	1.3	30
125	Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. Haematologica, 2016, 101, 634-643.	3.5	30
126	Incidence, significance, and persistence of human coronavirus infection in hematopoietic stem cell transplant recipients. Bone Marrow Transplantation, 2019, 54, 1058-1066.	2.4	30

#	Article	IF	Citations
127	Hematological manifestations of COVID-19. Leukemia and Lymphoma, 2020, 61, 2790-2798.	1.3	30
128	Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments. Clinical Advances in Hematology and Oncology, 2014, 12, 565-73.	0.3	30
129	Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. Bone Marrow Transplantation, 1994, 13, 461-4.	2.4	28
130	Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant. Leukemia and Lymphoma, 2012, 53, 1552-1557.	1.3	27
131	Outcome of Lower-Intensity Allogeneic Transplantation in Non-Hodgkin Lymphoma after Autologous Transplantation Failure. Biology of Blood and Marrow Transplantation, 2012, 18, 1255-1264.	2.0	27
132	Myasthenia gravis, an autoimmune manifestation of lymphoma and lymphoproliferative disorders: case reports and review of literature. Leukemia and Lymphoma, 2012, 53, 371-380.	1.3	27
133	Comparison of Short-Term Response and Long-Term Outcomes after Initial Systemic Treatment of Chronic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2011, 17, 124-132.	2.0	26
134	Mycobacterial spindle cell pseudotumour: epidemiology and clinical outcomes. Journal of Clinical Pathology, 2018, 71, 626-630.	2.0	26
135	A Phase 1-11 Study of High-Dose Thiotepa, Busulfan and Cyclophosphamide as a Preparative Regimen for Autologous Transplantation for Malignant Lymphoma. Leukemia and Lymphoma, 1995, 17, 427-433.	1.3	25
136	Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. Blood Advances, 2019, 3, 1858-1867.	5.2	25
137	Pregnancy associated with lupus anticoagulant and heparin induced thrombocytopenia: management with a low molecular weight heparinoid. Thrombosis Research, 1991, 62, 23-29.	1.7	24
138	Invasive Aspergillus sinusitis During Bone Marrow Transplantation. Scandinavian Journal of Infectious Diseases, 1997, 29, 436-438.	1.5	24
139	Epidemiology of Vancomycin-Resistant Enterococci Among Patients on an Adult Stem Cell Transplant Unit: Observations From an Active Surveillance Program. Infection Control and Hospital Epidemiology, 2008, 29, 1019-1025.	1.8	24
140	Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML. Bone Marrow Transplantation, 2010, 45, 1692-1698.	2.4	24
141	Implementation of Molecular Surveillance After a Cluster of Fatal Toxoplasmosis at 2 Neighboring Transplant Centers. Clinical Infectious Diseases, 2016, 63, 565-568.	5.8	24
142	Haploidentical cord transplantationâ€"The best of both worlds. Seminars in Hematology, 2016, 53, 257-266.	3.4	24
143	Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. JCO Precision Oncology, 2019, 3, 1-12.	3.0	24
144	Colonization With Fluoroquinolone-Resistant Enterobacterales Decreases the Effectiveness of Fluoroquinolone Prophylaxis in Hematopoietic Cell Transplant Recipients. Clinical Infectious Diseases, 2021, 73, 1257-1265.	5.8	24

#	Article	IF	Citations
145	Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial. Blood, 2019, 134, 4103-4103.	1.4	24
146	Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients. Biology of Blood and Marrow Transplantation, 1997, 3, 150-6.	2.0	24
147	Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. American Journal of Hematology, 2001, 67, 227-233.	4.1	23
148	Immune reconstitution after combined haploidentical and umbilical cord blood transplant. Leukemia and Lymphoma, 2013, 54, 1242-1249.	1.3	23
149	A strategy to reduce donor-specific HLA Abs before allogeneic transplantation. Bone Marrow Transplantation, 2014, 49, 722-724.	2.4	23
150	Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. Leukemia and Lymphoma, 2019, 60, 1626-1631.	1.3	23
151	Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia. Bone Marrow Transplantation, 1999, 23, 977-981.	2.4	22
152	The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma. Blood Reviews, 2006, 20, 235-244.	5.7	22
153	Introduction to the Reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 563-564.	2.0	22
154	Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk. Leukemia and Lymphoma, 2019, 60, 1693-1696.	1.3	22
155	Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant. Experimental Hematology and Oncology, 2019, 8, 1.	5.0	21
156	Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir. Bone Marrow Transplantation, 1997, 20, 491-495.	2.4	20
157	Stem cell transplantation in follicular lymphoma: progress at last?. Bone Marrow Transplantation, 2004, 34, 929-938.	2.4	20
158	Granulocyte Colony-Stimulating Factor-Based Stem Cell Mobilization in Patients with Sickle Cell Disease. Biology of Blood and Marrow Transplantation, 2008, 14, 719-723.	2.0	20
159	High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk Acute Myeloid Leukemia (AML). Leukemia and Lymphoma, 2012, 53, 445-450.	1.3	20
160	Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. Biology of Blood and Marrow Transplantation, 2016, 22, 1065-1072.	2.0	20
161	Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 359-365.	2.0	20
162	High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplantation, 2019, 54, 2027-2038.	2.4	20

#	Article	IF	Citations
163	Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. Npj Precision Oncology, 2021, 5, 44.	5.4	20
164	Central nervous system relapse of lymphoid malignancies in adults: The role of high-dose chemotherapy. Annals of Oncology, 1997, 8, 515-524.	1.2	19
165	Allogeneic Transplantation for Low-Grade Lymphoma: Long-Term Follow-Up. Journal of Clinical Oncology, 2000, 18, 702-702.	1.6	19
166	Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1. Biology of Blood and Marrow Transplantation, 2000, 6, 190-197.	2.0	19
167	Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 297-303.	0.4	19
168	Unrelated donor transplantation over the age of 55. Are we merely getting (b)older?. Leukemia, 2005, 19, 31-33.	7.2	18
169	Allogeneic stem cell transplantation in follicular lymphoma: recent progress and controversy. Hematology American Society of Hematology Education Program, 2009, 2009, 610-618.	2.5	18
170	A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes. Bone Marrow Transplantation, 2013, 48, 1437-1443.	2.4	18
171	How we handled the dextran shortage: an alternative washing or dilution solution for cord blood infusions. Transfusion, 2015, 55, 1147-1153.	1.6	18
172	Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalanâ€“Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 456-461.	2.0	18
173	Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. Biology of Blood and Marrow Transplantation, 2018, 24, 997-1004.	2.0	18
174	Hematology and oncology clinical care during the coronavirus disease 2019 pandemic. Ca-A Cancer Journal for Clinicians, 2020, 70, 349-354.	329.8	18
175	Phase II Trial of Low Dose, Subcutaneous Decitabine in Myelofibrosis. Blood, 2008, 112, 2809-2809.	1.4	18
176	Clinical outcomes of patients with desmoplastic small round cell tumor of the peritoneum undergoing autologous HCT: a CIBMTR retrospective analysis. Bone Marrow Transplantation, 2012, 47, 1455-1458.	2.4	17
177	Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant. Leukemia and Lymphoma, 2014, 55, 2866-2873.	1.3	17
178	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. , 2016, 4, 90.		17
179	Cord blood chimerism and relapse after haplo-cord transplantation. Leukemia and Lymphoma, 2017, 58, 288-297.	1.3	17
180	Impact of a Multiplexed Polymerase Chain Reaction Panel on Identifying Diarrheal Pathogens in Hematopoietic Cell Transplant Recipients. Clinical Infectious Diseases, 2020, 71, 1693-1700.	5.8	17

#	Article	IF	Citations
181	Clinical activity of arsenic trioxide in Burkitt-like lymphoma. Leukemia, 2003, 17, 271-272.	7.2	16
182	Successful allogeneic transplantation of patients with suspected prior invasive mold infection. Leukemia and Lymphoma, 2007, 48, 1799-1805.	1.3	16
183	Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. Leukemia and Lymphoma, 2010, 51, 1241-1250.	1.3	16
184	Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. Leukemia and Lymphoma, 2010, 51, 995-1006.	1.3	16
185	T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse. Leukemia and Lymphoma, 2011, 52, 214-222.	1.3	16
186	Influence of related donor age on outcomes after peripheral blood stem cell transplantation. Cytotherapy, 2012, 14, 707-715.	0.7	16
187	Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas. Haematologica, 2022, 107, 1608-1618.	3.5	16
188	Endoscopic Sclerotherapy of Esophageal Varices. Journal of Clinical Gastroenterology, 1988, 10, 368-372.	2.2	15
189	Intensive Dose Ifosfamide and Etoposide with G-CSF for Stem Cell Mobilization in Patients with Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 1999, 35, 317-324.	1.3	15
190	Hematopoietic Stem Cell Transplantation for Myelofibrosis. Seminars in Oncology, 2005, 32, 414-421.	2.2	15
191	Stem-Cell Transplantation for Sickle Cell Disease. New England Journal of Medicine, 2010, 362, 955-956.	27.0	15
192	A novel hematopoietic progenitor cell mobilization and collection algorithm based on preemptive CD34 enumeration. Transfusion, 2015, 55, 2010-2016.	1.6	15
193	Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel. Blood, 2019, 134, 2883-2883.	1.4	15
194	Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival. Bone Marrow Transplantation, 2001, 27, 397-404.	2.4	14
195	Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir. Bone Marrow Transplantation, 2003, 31, 813-816.	2.4	14
196	The Next Frontier for Stem Cell Transplantation. JAMA - Journal of the American Medical Association, 2010, 303, 1421.	7.4	14
197	The Addition of Low-Dose Total Body Irradiation to Fludarabine and Melphalan Conditioning in Haplocord Transplantation for High-Risk Hematological Malignancies. Transplantation, 2017, 101, e34-e38.	1.0	14
198	Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy- 1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood, 1995, 86, 2842-2848.	1.4	14

#	Article	IF	Citations
199	Autologous and allogeneic transplantation for aggressive NHL. Cytotherapy, 2002, 4, 223-240.	0.7	13
200	Interdigitating dendritic cell tumors in two patients exposed to topical calcineurin inhibitors. Leukemia and Lymphoma, 2007, 48, 816-818.	1.3	13
201	Fatal CMV pneumonitis in a lymphoma patient treated with rituximab. American Journal of Hematology, 2009, 84, 614-616.	4.1	13
202	Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices. Biology of Blood and Marrow Transplantation, 2018, 24, 288-293.	2.0	13
203	Bortezomib and Immune Globulin Have Limited Effects on Donor-Specific HLA Antibodies in Haploidentical Cord Blood Stem Cell Transplantation: Detrimental Effect of Persistent Haploidentical Donor-Specific HLA Antibodies. Biology of Blood and Marrow Transplantation, 2019, 25, e60-e64.	2.0	13
204	STEM CELL TRANSPLANTATION ELIMINATES ALLOANTIBODY IN A HIGHLY SENSITIZED PATIENT1. Transplantation, 2001, 72, 1653-1655.	1.0	13
205	Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma. Biology of Blood and Marrow Transplantation, 2004, 10, 386-394.	2.0	12
206	Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. Leukemia and Lymphoma, 2009, 50, 85-91.	1.3	12
207	Chronic Myelogenous Leukemia: Role of Stem Cell Transplant in the Imatinib Era. Hematology/Oncology Clinics of North America, 2011, 25, 1025-1048.	2.2	12
208	Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma. Current Opinion in Oncology, 2011, 23, 681-691.	2.4	12
209	Addition of Plerixafor to Mobilization Regimens in Autologous Peripheral Blood Stem Cell Transplants Does Not Affect the Correlation of Preharvest Hematopoietic Precursor Cell Enumeration with First-Harvest CD34+ Stem Cell Yield. Biology of Blood and Marrow Transplantation, 2012, 18, 1867-1875.	2.0	12
210	Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicity. Leukemia and Lymphoma, 2012, 53, 158-159.	1.3	12
211	Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation. Biology of Blood and Marrow Transplantation, 2015, 21, 552-558.	2.0	12
212	Early human herpes virus type 6 reactivation in umbilical cord blood allogeneic stem cell transplantation. Leukemia and Lymphoma, 2016, 57, 2555-2559.	1.3	12
213	Analysis of Chimerism Following Allogeneic Bone Marrow Transplantation by Fluorescent-in-Situ Hybridization. Leukemia and Lymphoma, 1997, 25, 463-467.	1.3	11
214	Differences in Characteristics of US Hematopoietic Stem Cell Transplantation Centers by Proportion of Racial or Ethnic Minorities. Biology of Blood and Marrow Transplantation, 2005, 11, 988-998.	2.0	11
215	Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leukemia and Lymphoma, 2008, 49, 531-537.	1.3	11
216	Outcomes of Allogeneic Stem Cell Transplant for Elderly Patients with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2020, 26, 789-797.	2.0	11

#	Article	IF	Citations
217	Cord blood maternal microchimerism following unrelated cord blood transplantation. Bone Marrow Transplantation, 2021, 56, 1090-1098.	2.4	11
218	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. , 2020, 8, e001235.		11
219	Clinical Predictors of Transplant Related Mortality after Reduced Intensity Allogeneic Stem Cell Transplantation (RIST).. Blood, 2004, 104, 1145-1145.	1.4	11
220	Reduced Intensity vs Myeloablative Conditioning for HLA Matched Sibling Transplantation in Follicular Lymphoma.. Blood, 2005, 106, 656-656.	1.4	11
221	Risk Factors for Acute Graft-Versus-Host Disease After Allogeneic Blood Stem Cell Transplantation. Blood, 1999, 94, 1465-1470.	1.4	11
222	High-dose melphalan allows durable engraftment of allogeneic bone marrow. Bone Marrow Transplantation, 1995, 15, 321-3.	2.4	11
223	Personalized Treatment of Lymphoma: Promise and Reality. Seminars in Oncology, 2011, 38, 225-235.	2.2	10
224	Alternative Donor Transplantationâ€”â€œMixing and Matchingâ€: the Role of Combined Cord Blood and Haplo-Identical Donor Transplantation (Haplo-Cord SCT) as a Treatment Strategy for Patients Lacking Standard Donors?. Current Hematologic Malignancy Reports, 2015, 10, 1-7.	2.3	10
225	A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2017, 23, 930-937.	2.0	10
226	Refractory T-Cell Prolymphocytic Leukemia with JAK3 Mutation: In Vitro and Clinical Synergy of Tofacitinib and Ruxolitinib. Blood, 2015, 126, 5486-5486.	1.4	10
227	Predictors of Covid-19 Vaccination Response After In-Vivo T-Cellâ€“Depleted Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 618.e1-618.e10.	1.2	10
228	Toxicity of single daily dose gentamicin in stem cell transplantation. Bone Marrow Transplantation, 1999, 24, 57-61.	2.4	9
229	Safety and outcome after fludarabineâ€“thiotepaâ€“TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies. Bone Marrow Transplantation, 2003, 32, 9-13.	2.4	9
230	Follicular lymphoma: a historical overview. Leukemia and Lymphoma, 2007, 48, 232-243.	1.3	9
231	C5b-9 and MASP2 deposition in skin and bone marrow microvasculature characterize hematopoietic stem cell transplant-associated thrombotic microangiopathy. Bone Marrow Transplantation, 2022, 57, 1445-1447.	2.4	9
232	High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant. Bone Marrow Transplantation, 2000, 26, 333-338.	2.4	8
233	Order of patient entry influences outcome for metastatic renal cell cancer after non-myeloablative allogeneic stem cell transplantation. British Journal of Haematology, 2006, 132, 747-754.	2.5	8
234	Distinct functions of erythropoietin and stem cell factor are linked to activation of mTOR kinase signaling pathway in human erythroid progenitors. Cytokine, 2013, 61, 329-335.	3.2	8

#	Article	IF	Citations
235	Topping it up: methods to improve cord blood transplantation outcomes by increasing the number of CD34+ cells. Cytotherapy, 2015, 17, 723-729.	0.7	8
236	Engraftment for CD34 selected stem cell products is not compromised by cryopreservation. Transfusion, 2016, 56, 893-898.	1.6	8
237	Baloxavir for the treatment of Influenza in allogeneic hematopoietic stem cell transplant recipients previously treated with oseltamivir. Transplant Infectious Disease, 2020, 22, e13336.	1.7	8
238	Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL). Blood, 2019, 134, 242-242.	1.4	8
239	Thrombotic thrombocytopenic purpura after cephalosporin administration: a possible relationship. Transfusion, 2003, 43, 1317-1321.	1.6	7
240	Chimerism does not predict for outcome after alemtuzumab based conditioning. Bone Marrow Transplantation, 2007, 40, 181-181.	2.4	7
241	Features of Frailty Are Surprisingly Common in Adults 50 Years and Older Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) in the Modern Era. Biology of Blood and Marrow Transplantation, 2011, 17, S302.	2.0	7
242	Identification of high-risk amino-acid substitutions in hematopoietic cell transplantation: a challenging task. Bone Marrow Transplantation, 2016, 51, 1342-1349.	2.4	7
243	Haplo-cord transplant: HLA-matching determines graft dominance. Leukemia and Lymphoma, 2017, 58, 1512-1514.	1.3	7
244	The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data. Leukemia and Lymphoma, 2018, 59, 256-258.	1.3	7
245	Successful Treatment of Mature T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: The Largest Multicenter Retrospective Analysis. Blood, 2020, 136, 35-36.	1.4	7
246	Allogeneic hematopoietic transplantation for chronic lymphocytic leukemia and lymphoma: Potential for nonablative preparative regimens. Current Oncology Reports, 2000, 2, 182-191.	4.0	6
247	Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection. Blood, 2004, 103, 4373-4374.	1.4	6
248	Severe intestinal graft-versus-host disease following autologous stem cell transplantation. Bone Marrow Transplantation, 2006, 38, 391-392.	2.4	6
249	Autologous stem cell transplant in human immunodeficiency virus-positive patients with lymphoid malignancies: focus on infectious complications. Leukemia and Lymphoma, 2013, 54, 885-888.	1.3	6
250	Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tabelecleucel on an Expanded Access Program. Blood, 2019, 134, 4071-4071.	1.4	6
251	Superior Survival after Autologous vs. Allogeneic Hematopoietic Stem Cell Transplantation (HCT) for Diffuse Large B-Cell Lymphoma (DLBCL) Not Explained by Differences in Chemosensitivity.. Blood, 2006, 108, 3021-3021.	1.4	6
252	Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies. Blood, 2021, 138, 1791-1791.	1.4	6

#	Article	IF	Citations
253	Antithymocyte globulin for graft-versus-host disease prophylaxis: mistakenly maligned. Leukemia and Lymphoma, 2015, 56, 841-842.	1.3	5
254	Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response. Blood Advances, 2020, 4, 5146-5156.	5.2	5
255	Autologous transplant for primary mediastinal B-cell lymphoma. Expert Review of Hematology, 2009, 2, 31-36.	2.2	4
256	Methodological and Logistical Considerations to Study Design and Data Collection in Racial/Ethnic Minority Populations Evaluating Outcome Disparity in Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 903-909.	2.0	4
257	Cord blood transplant: the glass is half fullâ€"can we do better?. Leukemia and Lymphoma, 2011, 52, 554-555.	1.3	4
258	Controversies in Multiple Myeloma: to Transplant or Not?. Current Hematologic Malignancy Reports, 2014, 9, 360-367.	2.3	4
259	Against the odds: haplo-cord grafts protect from GvHD and relapse. Bone Marrow Transplantation, 2017, 52, 1590-1591.	2.4	4
260	Earlier may be better: the role of extracorporeal photopheresis (ECP) as prevention of GVHD after allogeneic transplant. Leukemia and Lymphoma, 2018, 59, 272-273.	1.3	4
261	CORRELATIVE ANALYSES OF CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL EVENTS IN TISAGENLECLEUCEL-TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS. Hematological Oncology, 2019, 37, 308-310.	1.7	4
262	Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes. Biology of Blood and Marrow Transplantation, 2019, 25, 466-473.	2.0	4
263	Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy. Transplantation and Cellular Therapy, 2021, 27, 993.e1-993.e8.	1.2	4
264	Haplo+cord transplantation: Neutrophil and platelet recovery and long-term survival compared to double umbilical cord blood (UCB) transplantationâ€"A case-cohort analysis.. Journal of Clinical Oncology, 2014, 32, 7004-7004.	1.6	4
265	Characteristics of engraftment after repeated autologous bone marrow transplantation. Experimental Hematology, 1990, 18, 785-8.	0.4	4
266	Preleukemic state preceding adult acute lymphoblastic leukemia. American Journal of Medicine, 1990, 89, 657-662.	1.5	3
267	Autologous and allogeneic stem cell transplantation in follicular lymphoma. Transfusion and Apheresis Science, 2005, 32, 45-53.	1.0	3
268	Standardizing chronic graft-versus-host disease. Future Oncology, 2006, 2, 459-462.	2.4	3
269	Toxicity of high dose BCNU: How much is too much?. Leukemia and Lymphoma, 2006, 47, 1447-1448.	1.3	3
270	mTOR Inhibition in Lymphoma: A Rational and Promising Strategy. Letters in Drug Design and Discovery, 2007, 4, 224-231.	0.7	3

#	Article	IF	Citations
271	Cardiac tamponade in a patient with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2007, 48, 829-832.	1.3	3
272	Nonmyeloablative conditioning for relapsed follicular lymphoma. Blood, 2008, 112, 2585-2586.	1.4	3
273	Geriatric Assessment (GA) May Identify Vulnerable Older Allogeneic Hematopoietic Cell Transplantation (HCT) Recipients. Biology of Blood and Marrow Transplantation, 2009, 15, 102-103.	2.0	3
274	Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Advanced Hematologic Malignancies: Unexpected Renal Toxicity. Biology of Blood and Marrow Transplantation, 2009, 15, 105.	2.0	3
275	Clofarabine as a bridge to hematopoietic stem cell transplant. Leukemia and Lymphoma, 2017, 58, 230-232.	1.3	3
276	Cord blood transplants supported by unrelated donor CD34+ progenitor cells. Bone Marrow Transplantation, 2020, 55, 2298-2307.	2.4	3
277	Reduced-Intensity and Nonmyeloablative Conditioning Regimens. Cancer Treatment and Research, 2009, 144, 209-232.	0.5	3
278	Re-Induction and Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial. Blood, 2019, 134, 5642-5642.	1.4	3
279	Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered. Blood, 2020, 136, 42-44.	1.4	3
280	Molecular Inhibition of mTOR with Temsirolimus (TORISELâ„¢, CCI-779) Is a Promising Strategy in Relapsed NHL: The University of Chicago Phase II Consortium.. Blood, 2006, 108, 2483-2483.	1.4	3
281	Phase II Study of Decitabine in Myelofibrosis with Myeloid Metaplasia.. Blood, 2006, 108, 4923-4923.	1.4	3
282	Autologous (auto) Versus Allogeneic (allo) Hematopoietic Cell Transplantation (HCT) for T-NHL: A CIBMTR Analysis. Blood, 2010, 116, 689-689.	1.4	3
283	Haplo-Cord Transplantation Vs Unrelated Donor Stem Cell Transplantation in Patients with AML/MDS Older Than 50. Blood, 2014, 124, 1235-1235.	1.4	3
284	Use of eculizumab in autologous hematopoietic stem cell transplantation-associated thrombotic microangiopathy in two adults. Leukemia and Lymphoma, 2021, , 1-5.	1.3	3
285	A Phase I Study of Selinexor and R-ICE in Patients with Relapsed/Refractory Aggressive B-Cell Lymphomas. Blood, 2020, 136, 7-8.	1.4	3
286	Ganciclovir and high-dose valacyclovir reduce cytomegalovirus reactivation in patients receiving allogeneic stem cell transplantation with Campath-1Hâ€“based conditioning regimens. Biology of Blood and Marrow Transplantation, 2005, 11, 94.	2.0	2
287	2007: The year in review forLeukemia and Lymphoma. Leukemia and Lymphoma, 2008, 49, 1-3.	1.3	2
288	Stem cell transplantation for indolent lymphoma. Blood Reviews, 2011, 25, 223-228.	5.7	2

#	Article	IF	Citations
289	Allogeneic Hematopoietic Cell Transplantation for Therapy-Related Myeloid Leukemia following Orthotopic Cardiac Transplantation. Case Reports in Hematology, 2013, 2013, 1-3.	0.4	2
290	Microchimerism and allogeneic transplantation. Chimerism, 2013, 4, 109-110.	0.7	2
291	Validating and implementing the use of an infusion pump for the administration of thawed hematopoietic progenitor cellsâ€"a singleâ€institution experience. Transfusion, 2018, 58, 339-344.	1.6	2
292	INTRAVENOUS IMMUNOGLOBULIN THERAPY USE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH TISAGENLECLEUCEL IN THE JULIET TRIAL. Hematological Oncology, 2019, 37, 505-507.	1.7	2
293	Impact of alemtuzumab dosing and low-dose total body irradiation on cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation. Leukemia and Lymphoma, 2020, 61, 3024-3026.	1.3	2
294	Combining haplo-identical and cord blood stem cell grafts â€“ might the whole be greater than the sum of its parts?. Leukemia and Lymphoma, 2020, 61, 753-756.	1.3	2
295	Colonization with Gastrointestinal Pathogens Prior to Hematopoietic Cell Transplantation and Associated Clinical Implications. Transplantation and Cellular Therapy, 2021, 27, 499.e1-499.e6.	1.2	2
296	Update of a phase II, multicenter study of high-dose chemotherapy with autologous stem cell transplant followed by maintenance romidepsin for T-cell lymphoma.. Journal of Clinical Oncology, 2021, 39, 7533-7533.	1.6	2
297	A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma. Blood, 2019, 134, 4033-4033.	1.4	2
298	High Doses of Targeted Radiation with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood, 2020, 136, 30-31.	1.4	2
299	Prospective Study of Immunomodulation with GM-CSF, IL-2, and Rituximab Following Autologous Stem Cell Transplant (SCT) in Patients with Relapsed Lymphomas.. Blood, 2004, 104, 918-918.	1.4	2
300	Alemtuzumab Reduces Chronic Graft Versus Host Disease (cGVHD) and Treatment Related Mortality (TRM) after Reduced Intensity Conditioning for AML and MDS.. Blood, 2007, 110, 1076-1076.	1.4	2
301	Pilot Study Of Regulatory T Cell Depletion In The Setting Of Autologous Stem Cell Transplantation For Multiple Myeloma. Blood, 2013, 122, 4607-4607.	1.4	2
302	Predictors and GVL Effects of UCB Chimerism after Haplo-Cord Transplant. Blood, 2015, 126, 4385-4385.	1.4	2
303	Adenovirus viremia after inÂvivo T-cell depleted allo-transplant in adults: low lymphocyte counts are associated with uncontrolled viremia and fatal outcomes. Leukemia and Lymphoma, 2022, 63, 435-442.	1.3	2
304	The Outcomes of Second Allogeneic Stem Cell Transplantation for Disease Relapse after T Cell Depleted Allogeneic Stem Cell Transplantation: A Single Center Experience-University of Chicago. Blood, 2014, 124, 2509-2509.	1.4	2
305	Screening Chest CT Prior to Allogenic Transplantation - High Rates of Occult Abnormalities. Blood, 2021, 138, 1777-1777.	1.4	2
306	Therapeutic options for patients with hodgkinâ€™s disease and non-hodgkinâ€™s lymphoma who relapse after autologous transplant. Current Treatment Options in Oncology, 2005, 6, 279-287.	3.0	1

#	Article	IF	Citations
307	Autologous transplantation for follicular lymphoma? Not too soon!. Blood, 2006, 108, 2496-2497.	1.4	1
308	T-Cellâ€“Depleted Reduced-Intensity Conditioning Transplantation for Lymphoma: Do Donor Lymphocyte Infusions Really Matter?. Journal of Clinical Oncology, 2011, 29, e243-e243.	1.6	1
309	Second allogeneic transplantation: ever? never? or sometimes. Leukemia and Lymphoma, 2017, 58, 1279-1280.	1.3	1
310	A renaissance for autologous transplantation in follicular lymphoma?. Leukemia and Lymphoma, 2019, 60, 3-5.	1.3	1
311	Detection and Characterization of Influenza B Virus with Reduced Neuraminidase Susceptibility in a Stem Cell Transplant Recipient. Open Forum Infectious Diseases, 2019, 6, ofz493.	0.9	1
312	MULTI-CENTER PHASE II STUDY OF ORAL AZACITIDINE (CC-486) PLUS CHOP AS INITIAL TREATMENT FOR PERIPHERAL T-CELL LYMPHOMA. Hematological Oncology, 2019, 37, 560-561.	1.7	1
313	Alternative Donor Transplantation for Lymphoid Malignancies: How Far We Have Come. Journal of Clinical Oncology, 2020, 38, 1501-1504.	1.6	1
314	Seven Years of Haplo-Cord Transplantation: Immune Reconstitution and Outcomes Using Anti-Thymocyte Globulin. Biology of Blood and Marrow Transplantation, 2020, 26, S309.	2.0	1
315	Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma. Leukemia and Lymphoma, 2021, 62, 1629-1638.	1.3	1
316	STEM CELL TRANSPLANTATION FOR A HIGHLY SENSITIZED PATIENT. Transplantation, 1999, 67, S14.	1.0	1
317	Results from the Myeloproliferative Neoplasm Patient Care Survey: Patient Care Opportunities and Challenges. Blood, 2018, 132, 4289-4289.	1.4	1
318	Does Presence of Persistent Molecular Mutations Matter in AML Patients Undergoing Allogeneic Stem Cell Transplant?. Blood, 2018, 132, 2172-2172.	1.4	1
319	Fludarabine Melphalan and Alemtuzumab (Campath) Conditioning for Pts with High Risk Myeloid Malignancies. High Cure Rate for Pts with Low Leukemia Burden.. Blood, 2004, 104, 2321-2321.	1.4	1
320	Leukemic Relapse after Allogeneic Stem Cell Transplantation with a T-Cell Depleted Reduced Intensity Conditioning (RIST) Regimen.. Blood, 2005, 106, 2022-2022.	1.4	1
321	Preliminary Results of Combined Haploidentical-Cord Blood Transplantation for Patients Lacking HLA Identical Donors. Blood, 2008, 112, 3015-3015.	1.4	1
322	Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NMHCT) for Patients Relapsing after Autologous Stem Cell Transplantation (autoHCT) for B Cell Non-Hodgkin Lymphoma (NHL). Blood, 2008, 112, 459-459.	1.4	1
323	Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation (Hct) in Patients with Advanced Hematologic Malignancies: A Phase Iâ€“II Study. Blood, 2008, 112, 4381-4381.	1.4	1
324	A Prospective Multicenter Phase II Trial of Pentostatin in Adult Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease (cGvHD): A Cancer and Leukemia Group B/Eastern Cooperative Oncology Group Study.. Blood, 2009, 114, 2238-2238.	1.4	1

#	Article	IF	Citations
325	Immune-reconstitution after combined haploidentical and umbilical cord blood transplantation.. Journal of Clinical Oncology, 2012, 30, 6535-6535.	1.6	1
326	Targeting the Epichaperome As an Effective Precision Medicine Approach in a Novel PML-SYK Fusion Acute Myeloid Leukemia. Blood, 2018, 132, 1435-1435.	1.4	1
327	Allogeneic transplant graft source â€“ conditioning â€“ GVHD prophylaxis: donâ€™t mix and match!. Leukemia and Lymphoma, 2021, , 1-3.	1.3	1
328	Phase I/II Clinical Trial of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas. Blood, 2020, 136, 43-44.	1.4	1
329	Reduced duration of cytopenias following melphalan conditioning and autografting for multiple myeloma. Blood, 2002, 99, 4251-4252.	1.4	0
330	Transplantation for myelofibrosis: yes! But for whom?. Blood, 2003, 102, 3857-3857.	1.4	0
331	Long-term follow up after non-myeloablative allogeneic stem cell transplantation for renal cell carcinoma: the university of Chicago experience. Biology of Blood and Marrow Transplantation, 2004, 10, 10.	2.0	0
332	A multi-institutional study of extracorporeal photophoresis (ECP) with UvadexÂ® for the prevention of acute graft vs. host disease (aGvHD) in patients (pts) undergoing allogeneic hematopoietic progenitor cell transplants (allo-HPCT) with myeloablative conditioning. Biology of Blood and Marrow Transplantation, 2004, 10, 53.	2.0	0
333	Autologous transplantation for newly diagnosed follicular lymphoma: cure at last or not yet?. Blood, 2004, 104, 2613-2614.	1.4	0
334	A multi-institutional study of extracorporeal photoimmune therapy (ECP) with UVADEXÂ® for the prevention of acute GVHD in patients (pts) undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation (AHCT). Biology of Blood and Marrow Transplantation, 2005, 11, 37.	2.0	0
335	The relationship of day 30 and day 100 donor chimerism to clinical outcomes following reduced-intensity allogeneic transplantation for hematologic malignancies. Biology of Blood and Marrow Transplantation, 2006, 12, 34.	2.0	0
336	28: A multicenter prospective randomized Phase II study in patients with corticosteroid-refractory/dependent/intolerant chronic cutaneous GVHD given either extracorporeal photoimmune therapy with UVADEXÂ® in conjunction with conventional therapy or conventional therapy alone. Biology of Blood and Marrow Transplantation, 2007, 13, 13.	2.0	0
337	223: C-reactive protein (CRP) may predict transplant-related mortality after allogeneic hematopoietic cell transplant (HCT). Biology of Blood and Marrow Transplantation, 2007, 13, 82.	2.0	0
338	159: Feasibility of Clofarabine Cytoreduction before Initiation of Allogeneic Stem Cell Transplant Regimen During the Cytopenic Phase for Patients with Refractory Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation, 2008, 14, 60.	2.0	0
339	Superiority of Reduced-Intensity Conditioning for Hodgkin's Lymphoma. Journal of Clinical Oncology, 2008, 26, 4045-4046.	1.6	0
340	Late relapse following allogeneic transplant for chronic lymphocytic leukemia: How good are graft versus leukemia effects?. Leukemia and Lymphoma, 2008, 49, 1651-1652.	1.3	0
341	BK Virus Infection is Associated with Hematuria and Renal Impairment in Recipients of Allogeneic Hematopoetic Stem Cell Transplants. Biology of Blood and Marrow Transplantation, 2009, 15, 9.	2.0	0
342	Donor Policies for Stem Cell Transplantationâ€”Reply. JAMA - Journal of the American Medical Association, 2010, 304, 524.	7.4	0

#	Article	IF	Citations
343	Allogeneic transplant for peripheral T-cell lymphoma: a sparkle of hope and many questions. Leukemia and Lymphoma, 2011, 52, 1415-1417.	1.3	0
344	Older Sibling Donors Remain an Excellent Option: Older Donor Age and Lower CD34 Infused Do Not Adversely Impact Outcomes for Matched Sibling Peripheral Blood Stem Cell (PBSC) Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, S289.	2.0	0
345	HLA Antibodies in Combined Related Haploidentical-Unrelated Umbilical Cord Stem Cell Transplants. Biology of Blood and Marrow Transplantation, 2011, 17, S301.	2.0	0
346	cGVHD of skin: simple tools, great advances. Blood, 2012, 120, 2537-2538.	1.4	0
347	Listen to Thy Patient: Poor Quality of Life (QoL) Reported by Older Adults Prior to Allogeneic Stem Cell Transplantation (allo-HCT) Is Independently Associated with Worse Transplant Outcomes. Biology of Blood and Marrow Transplantation, 2012, 18, S227.	2.0	0
348	A Center Specific Guide Successfully Informs Patients About Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, S385.	2.0	0
349	Great expectations? Conditioning with busulfan, melphalan and thiotepa in recurrent Hodgkin lymphoma. Leukemia and Lymphoma, 2014, 55, 476-477.	1.3	0
350	To the end of chronic lymphocytic leukemia: what should be the role of allogeneic transplant?. Leukemia and Lymphoma, 2014, 55, 1221-1222.	1.3	0
351	Allografting versus Autografting for Follicular Lymphoma: AnÂOngoing Conundrum. Biology of Blood and Marrow Transplantation, 2015, 21, 2035-2036.	2.0	0
352	A new â€œageâ€•for high dose therapy and autologous stem cell transplant. Leukemia and Lymphoma, 2015, 56, 2233-2234.	1.3	0
353	HLA: revisiting an old suspect in the complex pathogenesis of posttransplant lymphoproliferative disorders. Leukemia and Lymphoma, 2016, 57, 2241-2242.	1.3	0
354	1581. Impact of Colonization with Fluoroquinolone-Resistant Enterobacteriaceae on the Risk of Gram-Negative Bacteremia in Hematopoietic Stem Cell Transplant Recipients Who Receive Prophylactic Levofloxacin. Open Forum Infectious Diseases, 2018, 5, S494-S494.	0.9	0
355	Hematopoietic Recovery after in-Vivo T-Cell Depleted Allogeneic Stem Cell Transplant-Effects of Major ABO Incompatibility, CMV Viremia and Acute Gvhd. Biology of Blood and Marrow Transplantation, 2018, 24, S337.	2.0	0
356	Comparison of time to engraftment between autologous patients receiving washed versus non-washed cryopreserved peripheral blood stem cell products. Leukemia and Lymphoma, 2018, 59, 2829-2835.	1.3	0
357	Donor graft genotypes versus leukemia. Leukemia and Lymphoma, 2019, 60, 1606-1607.	1.3	0
358	The application of precision medicine in diagnosing familial Mediterranean fever. Leukemia and Lymphoma, 2019, 60, 2091-2093.	1.3	0
359	Allogeneic transplant for CML in chronic phase after failure of imatinib. Not needed or needlessly neglected?. Leukemia and Lymphoma, 2020, 61, 2783-2784.	1.3	0
360	An update on options of therapy for aggressive mantle cell lymphoma. Leukemia and Lymphoma, 2020, 61, 2036-2049.	1.3	0

#	Article	IF	Citations
361	High-dose lenalidomide and melphalan as conditioning for autologous stem cell transplantation in relapsed or refractory multiple myeloma.. Journal of Clinical Oncology, 2021, 39, 8021-8021.	1.6	0
362	Maintenance therapy after allogeneic transplant for acute myeloid leukemia: great expectations. Leukemia and Lymphoma, 2021, 62, 1-4.	1.3	0
363	Non-Hodgkinâ€™s Lymphoma. , 2003, , 295-318.		0
364	Distinct Functions of Erythropoietin and Stem Cell Factor Are Linked to Activation of p70S6/mTOR Kinase Signaling Pathway in Primary Erythroid Progenitors.. Blood, 2004, 104, 2175-2175.	1.4	0
365	Conditioning with Fludarabine (Flu)-Alkylator Is More Effective Cytoreduction Than Cyclophosphamide-Total Body Irradiation (Cy/TBI) for Refractory, Progressive Chronic Lymphatic Leukemia (CLL).. Blood, 2004, 104, 5045-5045.	1.4	0
366	Alemtuzumab (Campath 1-H) Exposure Correlates with Risk of Chronic Graft vs Host Disease and CMV Viremia after Allogeneic Transplantation.. Blood, 2005, 106, 1818-1818.	1.4	0
367	Autocrine Signaling by Osteopontin Regulates Actin Remodeling in Human Primary Erythroid Progenitors.. Blood, 2005, 106, 1667-1667.	1.4	0
368	New Cytogenetic Abnormalities Are Frequent in AML and MDS Relapsing after Allogeneic Hematopoietic Cell Transplantation (HCT).. Blood, 2006, 108, 3675-3675.	1.4	0
369	Pre-Transplant Biomarkers Predict GVHD and Treatment-Related Mortality in Patients Treated with Extracorporeal Photopheresis Prior to Allogeneic Bone Marrow Transplantation.. Blood, 2006, 108, 5182-5182.	1.4	0
370	Prospective Measurement of BK Virus Blood and Urine Levels, and Associations with Morbidity, in Recipients of Allogeneic Hematopoetic Stem Cell Transplants.. Blood, 2007, 110, 1973-1973.	1.4	0
371	Unrelated Donor (URD) Searches in African-Americans with Hematologic Malignancies: Paucity of HLA Identical Donors.. Blood, 2007, 110, 5064-5064.	1.4	0
372	Identifying Amino Acid Substitution Positions Associated with Day 100 Survival in Unrelated Donor Stem Cell Transplant Using Random Forest Analysis. Blood, 2008, 112, 3012-3012.	1.4	0
373	A Phase II Prospective Feasibility Study of Clofarabine Cytoreduction Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed or Refractory Acute Leukemias and Advanced Myelodysplastic Syndromes. Blood, 2011, 118, 496-496.	1.4	0
374	Association of clofarabine (Clo)-associated GFR decline (GFRd) with dose andÂAUC.. Journal of Clinical Oncology, 2012, 30, e13120-e13120.	1.6	0
375	Identification of High Risk HLA Class I Amino Acid Substitutions in Hematopoietic Stem Cell Transplantation.. Blood, 2012, 120, 3050-3050.	1.4	0
376	Haplo-cord Transplantation: Overcoming the Limitations of Umbilical Cord Blood (UCB) Transplantation (UCBT). Pancreatic Islet Biology, 2014, , 211-220.	0.3	0
377	Conventional and High Dose Chemotherapy for Lymphomas. , 1999, , 300-312.		0
378	Characterization of Tcra and Tcrb Repertoires in Acute Myeloid Leukemia Patients before and after Combined Haploidentical and Umbilical Cord Blood Transplant. Blood, 2014, 124, 2503-2503.	1.4	0

#	Article	IF	Citations
379	Hematopoietic Stem Cell Transplant in Novel Agent Era Is Associated with Improved Survival in Relapsed and Refractory Peripheral T-Cell Lymphoma. Blood, 2018, 132, 1640-1640.	1.4	0
380	Correlations between Pre-Transplant Treatment and Bone Marrow Response with Post-Transplant Outcomes in Patients with Myelodysplastic Syndrome Undergoing Allogeneic Stem Cell Transplantation. Blood, 2018, 132, 4391-4391.	1.4	0
381	CCR5 delta32 Cord & Haploidentical Grafts: Allogeneic Stem Cell Transplant for HIV+ /AML Patient: A Case Report from the Impaact P1107 Observational Study. Blood, 2018, 132, 2184-2184.	1.4	0
382	Comparison of Early Versus Delayed Filgrastim (G-CSF) Administration Following Autologous Stem Cell Transplantation in Patients with Multiple Myeloma - Real-World Data from a Single-Center Institution. Blood, 2019, 134, 5644-5644.	1.4	0
383	Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS. Blood, 2019, 134, 3324-3324.	1.4	0
384	Masp-2 Levels Following Allogeneic Hematopoietic Stem Cell Transplantation in Adults: Correlation with Development of a Thrombotic Microangiopathy and Implications for Therapy with Anti-Complement Agents. Blood, 2019, 134, 3305-3305.	1.4	0
385	Cellular Therapy for Follicular Lymphoma. , 2020, , 165-186.		0
386	Is less more? Viewpoint on empiric vancomycin therapy of fever and neutropenia after allogeneic stem cell transplantation. Leukemia and Lymphoma, 2021, 62, 255-256.	1.3	0
387	121â€...ICAM-1-specific affinity tuned CAR T cells expressing SSTR2 for real-time imaging. , 2021, 9, A130-A130.		0
388	Clinical Characteristics and Risk Factors for Adverse Outcomes of Influenza Infections in Hematopoietic Stem Cell Transplant Recipients. Blood, 2020, 136, 22-22.	1.4	0
389	Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells. Cancer Journal From Scientific American, 1997, 3 Suppl 1, S54-8.	0.8	0
390	Reply to Caldwell et al. Clinical Infectious Diseases, 2021, , .	5.8	0
391	The University of Chicago experience with a reduced intensity allogeneic peripheral blood stem cell transplant preparative regimen using fludarabine, cyclophosphamide, and antithymocyte globulin (ATG) in pts with a hematologic malignancy. Journal of Clinical Oncology, 2004, 22, 6626-6626.	1.6	0
392	Phase I study of AIC100 in relapsed and/or refractory advanced thyroid cancer and anaplastic thyroid cancer.. Journal of Clinical Oncology, 2022, 40, 6093-6093.	1.6	0